140 related articles for article (PubMed ID: 38100937)
1. Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF/ICSI procedures (DELTA Study).
Porcu-Buisson G; Maignien C; Swierkowski-Blanchard N; Rongières C; Ranisavljevic N; Oger P; Decanter C; Hocké C; Bry-Gauillard H; Grynberg M; Barrière P; Bernot M; Guivarc'h-Levêque A
Eur J Obstet Gynecol Reprod Biol; 2024 Feb; 293():21-26. PubMed ID: 38100937
[TBL] [Abstract][Full Text] [Related]
2. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study).
Blockeel C; Griesinger G; Rago R; Larsson P; Sonderegger YLY; Rivière S; Laven JSE
Front Endocrinol (Lausanne); 2022; 13():992677. PubMed ID: 36619578
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
4. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
Palomba S; Caserta D; Levi-Setti PE; Busnelli A
J Ovarian Res; 2024 Mar; 17(1):60. PubMed ID: 38486276
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
7. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
[TBL] [Abstract][Full Text] [Related]
8. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
[TBL] [Abstract][Full Text] [Related]
9. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
[TBL] [Abstract][Full Text] [Related]
10. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
Ishihara O; Arce JC;
Reprod Biomed Online; 2021 May; 42(5):909-918. PubMed ID: 33722477
[TBL] [Abstract][Full Text] [Related]
11. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.
Višnová H; Papaleo E; Martin FS; Koziol K; Klein BM; Mannaerts B
Reprod Biomed Online; 2021 Dec; 43(6):1019-1026. PubMed ID: 34756645
[TBL] [Abstract][Full Text] [Related]
14. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
Ishihara O; Klein BM; Arce JC;
Fertil Steril; 2021 Jun; 115(6):1478-1486. PubMed ID: 33272623
[TBL] [Abstract][Full Text] [Related]
15. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
16. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients.
Ishihara O; Nelson SM; Arce JC
Reprod Biomed Online; 2022 Jan; 44(1):177-184. PubMed ID: 34799275
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of ovarian stimulation with follitropin delta in a mixed regimen with HP-hMG: a real-world retrospective analysise.
Lim LJ; Kit AMF; Wong PS
Med J Malaysia; 2024 May; 79(3):275-280. PubMed ID: 38817059
[TBL] [Abstract][Full Text] [Related]
19. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
[TBL] [Abstract][Full Text] [Related]
20. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series.
Yacoub S; Cadesky K; Casper RF
J Ovarian Res; 2021 Feb; 14(1):31. PubMed ID: 33579321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
